Effectiveness and safety of alcohol-free minoxidil in the management of treatment-naive patients with androgenetic alopecia


  • Narendra G. Patwardhan Kelkar Nursing Home, Pune, Maharashtra, India
  • Dhanashree Bhide Dhadphale Nursing Home, Pune, Maharashtra, India
  • Sonal Shendkar Skinovate Laser and Cosmetic Surgery Center, Pune, Maharashtra, India




Anagen, Androgenic alopecia, Minoxidil, Procapil, Telogen, Hair loss


Background: Androgenetic alopecia (AGA) is a common dermatological condition in India, with potentially adverse psychosocial consequences. Here, we assess the effectiveness and safety of an alcohol-free, procapil-based formulation of minoxidil 5% in patients with AGA.

Methods: Treatment-naïve, male patients (aged 18 to ≤45 years) with AGA were enrolled in this open-label, single-arm, non-comparative, investigator-initiated study. The change in anagen/telogen ratio (ATR), hair density, and hair shaft thickness from baseline to days 45, 90, 135 and 180, investigator and patients’ global assessment for effectiveness and tolerability, and safety were assessed. A total of 53 men were enrolled.

Results: The mean (standard deviation [SD]) age of the study population was 28.3 (6.0) years. The mean (SD) ATR improvement post-treatment with minoxidil 5% was seen from day 90 (mean change: 0.4; p=0.009; 95% confidence interval [CI]: 0.1-0.7) till Day 180 (mean change: 0.4; p=0.011; 95% CI: 0.1-0.6). Improvement in hair density (p<0.01) and hair shaft thickness (p<0.01) across frontal, temporal, and occipital regions was also evident. The investigator assessment for effectiveness was ‘excellent’/’good’/’satisfactory’ for 90% of patients, which corroborated with patients’ assessment (90%) at day 180. All the investigators and patients indicated that minoxidil had ‘good’ tolerability for all patients. No adverse events were reported during the study.

Conclusions: Alcohol-free minoxidil 5% was found to have a good safety profile and was efficacious in Indian male patients with AGA, with a high level of patient acceptance.


Michel L, Reygagne P, Benech P, Jean-Louis F, Scalvino S, Ly Ka So S et al. Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signalling pathways. Br J Dermatol. 2017;177(5):1322-36.

Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: an update. Indian J Dermatol Venereol Leprol. 2013;79(5):613-25.

Pathomvanich D, Pongratananukul S, Thienthaworn P, Manoshai S. A random study of Asian male androgenetic alopecia in Bangkok, Thailand. Dermatol Surg. 2002;28(9):804-7.

Krupa Shankar D, Chakravarthi M, Shilpakar R. Male androgenetic alopecia: population-based study in 1,005 subjects. Int J Trichol. 2009;1(2):131-3.

Gupta S, Goyal I, Mahendra A. Quality of life assessment in patients with androgenetic alopecia. Int J Trichology. 2019;11(4):147-52.

Asfour L, Cranwell W, Sinclair R. Male androgenetic alopecia. In: Feingold KR, Anawalt B, Boyce A, Blackman M, Chrousos G, Corpas E et al editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.

Balakrishnan P, Shanmugam S, Lee WS, Lee WM, Kim J, Oh D et al. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm. 2009;377(1-2):1-8.

Moser K, Kriwet K, Naik A, Kalia YN, Guy RH. Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm. 2001;52(2):103-12.

Kiaee G, Javar HA, Kiaee B, Kiaei S. Preparation and characterization of liposome containing minoxidil and rosemary essential oil. J In Silico In Vitro Pharmacol. 2016;2:3.

Uprit S, Kumar Sahu R, Roy A, Pare A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J. 2013;21(4):379-85.

Padois K, Cantiéni C, Bertholle V, Bardel C, Pirot F, Falson F. Solid lipid nanoparticles suspension versus commercial solutions for dermal delivery of minoxidil. Int J Pharm. 2011;416(1):300-4.

Shorter K, Farjo NP, Picksley SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008;22(6):1725-36.

Malhi H, Irani AN, Rajvanshi P, Suadicani S, Spray D, McDonald T et al. KATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines. Implications for liver growth control and potential therapeutic targeting. J Biol Chem. 2000;275(34):26050-57.

Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141.

Olsen EA, Weiner MS, Amara IA, DeLong ER. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol. 1990;22(4):643-6.

Berger RS, Fu JL, Smiles KA, Turner CB, Schnell BM, Werchowski KM et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. 2003;149(2):354-62.

Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85.

Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol. 2002;46(2):309-12.

Lopedota A, Cutrignelli A, Denora N, Laquintana V, Lopalco A, Selva S et al. New ethanol and propylene glycol free gel formulations containing a minoxidil-methyl-β-cyclodextrin complex as promising tools for alopecia treatment. Drug Dev Ind Pharm. 2015;41(5):728-36.

Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186-94.

Tata S, Flynn GL, Weiner ND. Penetration of minoxidil from ethanol/propylene glycol solutions: effect of application volume and occlusion. J Pharm Sci. 1995;84(6):688-91.

Tata S, Weiner N, Flynn G. Relative influence of ethanol and propylene glycol cosolvents on deposition of minoxidil into the skin. J Pharm Sci. 1994;83(10):1508-10.

Mas-Chamberlin C, Mondon P, Lamy F, Peschard O, Lintner K. In: Krisdaphong P, editor. Reduction of hair-loss: matrikines and plant molecules to the rescue; Proceedings of the 7th Scientific Conference of the Asian Society of Cosmetic Chemists (ASCS): Toward a New Horizon: Uniting Cosmetic Science with Oriental Wisdom; March 7-9, 2005; Bangkok, Thailand: Society of Cosmetic Chemists of Thailand. 2005.

Maquart FX, Siméon A, Pasco S, Monboisse JC. Regulation of cell activity by the extracellular matrix: the concept of matrikines. J Soc Biol. 1999;193(4-5):423-8.

Trüeb RM. Serum biotin levels in women complaining of hair loss. Int J Trichology. 2016;8(2):73-7.

Mysore V, Parthasaradhi A, Kharkar RD, Ghoshal AK, Ganjoo A, Ravichandran G et al. Expert consensus on the management of androgenetic alopecia in India. Int J Trichology. 2019;11(3):101-6.

El-Ashmawy AA, El-Maadawy IH, El-Maghraby GM. Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata. J Dermatol Treat. 2018;29(1):55-64.

Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-74.

Dhurat R, Chitallia J, May TW, Jayaraaman AM, Madhukara J, Anandan S, et al. An open-label randomized multicenter study assessing the noninferiority of a caffeine-based topical liquid 0.2% versus minoxidil 5% solution in male androgenetic alopecia. Skin Pharmacol Physiol. 2017;30(6):298-305.

Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130-6.






Original Research Articles